Clinical Trial of Autologous Adipose Tissue Derived Stromal Cell Therapy for Ischemic Heart Failure
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01709279 |
Recruitment Status
:
Enrolling by invitation
First Posted
: October 18, 2012
Last Update Posted
: August 18, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Ischemic Heart Failure | Biological: adipose tissue derived stromal cells dosage | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 6 participants |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Study Start Date : | August 2012 |
Estimated Primary Completion Date : | August 2019 |
Estimated Study Completion Date : | September 2019 |

Arm | Intervention/treatment |
---|---|
adipose tissue derived stromal cells |
Biological: adipose tissue derived stromal cells dosage
intra-coronary administration of autologous adipose tissue derived stroma cells
|
- all cause harmful events [ Time Frame: 6 month ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 20 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Heart failure patients occured by prior ischemic event whose ejection fraction must be less than 40%.
Exclusion Criteria:
- Complicated severe other organ disease.
- Patient with malignancy.
- History of chemotherapy or irradiation within 4 weeks.
- Patient with immunodeficiency
- Pregnancy or possibility of pregnancy
- Candidate who are judged to be not applicable to this study by doctors.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01709279
Japan | |
Kanazawa University Hospital | |
Kanazawa, Ishikawa, Japan, 920-8641 |
Responsible Party: | Shuichi Kaneko, Professor, Kanazawa University |
ClinicalTrials.gov Identifier: | NCT01709279 History of Changes |
Other Study ID Numbers: |
1133 |
First Posted: | October 18, 2012 Key Record Dates |
Last Update Posted: | August 18, 2017 |
Last Verified: | August 2017 |
Keywords provided by Shuichi Kaneko, Kanazawa University:
Ischemic heart failure Myocardial regeneration ADRC |
Additional relevant MeSH terms:
Heart Failure Ischemia Heart Diseases Cardiovascular Diseases Pathologic Processes |